Henry Schein (HSIC) Corporate presentation summary

Scale and market position

• FY2025 global net sales of $13.2B; served more than 1M customers, with operations in 34 countries and approximately 25,000 team members.

• 2025 sales mix: Distribution and value-added services $11.1B (84%); Specialty Products and Other $1.5B (11%); Technology $675M (5%).

• Dental distribution and value-added services generated $6.9B, or 51% of gross sales; sales leadership in the U.S. and Canada, Europe, Australia and New Zealand, and Brazil.

• Medical distribution generated $4.3B, or 32% of gross sales; U.S. market share estimated at 20%, serving alternate-care and other healthcare settings.

Strategy and growth priorities

• BOLD + 1 aims to make the business more agile, customer-centric, digital, efficient, higher-growth and higher-margin by leveraging complementary operations.

• High-growth, high-margin businesses represent ~25% of sales, including corporate and owned brands and related services, and ~47% of non-GAAP operating income; private brands add ~10%.

• Goal: more than 50% of non-GAAP operating income from high-growth, high-margin businesses by end-2027, plus more than 10% from corporate brands.

• Value Creation Initiatives target over $200M in operating income improvements over the next few years through lower global SG&A and higher gross margins, including corporate-brand sales.

• Long-term earnings ambition: high-single-digit to low-double-digit growth, supported by cross-selling, new products, technology, innovation and strategic acquisitions.

Business and digital opportunities

• Specialty portfolio includes #2 global endodontics, #3 global implants and biomaterials excluding China, and oral surgery offerings; TriMed acquisition expanded into orthopedics.

• Dental technology generated $675M in 2025; three-quarters of revenue is recurring, and practice management software penetration is ~55% of U.S. dental practices.

• Technology serves ~100,000 customers worldwide, with opportunity to grow revenue per customer through practice software, analytics, revenue cycle management and patient engagement solutions.

• Digital priorities include AI-enabled product development, integrated clinical workflows and a global eCommerce platform launched in the U.S., Canada, Ireland and the UK.

• Distribution capabilities include 300K unique stocking SKUs, 22K private-brand products and next-day service to 90% of worldwide customers; network includes 38 distribution and 16 manufacturing facilities.